恒瑞医药任命新总裁，神经科医生出身，曾就职于阿斯利康

Group 1 - Heng Rui Pharma appointed Ms. Feng Ji as President and Chief Operating Officer, responsible for company management, while former President Dai Hongbin became Vice Chairman [2] - Ms. Feng Ji has over 30 years of experience in the pharmaceutical industry, having worked at Shanghai Renji Hospital, Novartis, Amgen, and AstraZeneca, with a strong background in sales, marketing, and international business operations [2] - The appointment comes at a critical time as Heng Rui Pharma aims to enhance its international presence, having submitted its application to the Hong Kong Stock Exchange on January 6 [2] Group 2 - Heng Rui Pharma has been focusing on the oncology field but is increasingly expanding into chronic disease areas, with 47 innovative pipelines in non-oncology fields, surpassing the number of oncology products in development [2] - Since 2023, the company has accelerated the launch of non-oncology innovative drugs in China, with nine new drugs including Henggrelin, Aimabuxitin, and others covering various fields such as metabolism, cardiovascular, and neuroscience [3] - Industry insiders believe that Ms. Feng Ji's extensive experience in chronic disease will facilitate Heng Rui's rapid expansion in the non-oncology sector [3]